Lewis obtained his PhD from the University of Cambridge in 2017 through a BBSRC/AstraZeneca CASE studentship, working on the development of novel algorithms for mode-of-action analysis. He spent two years as a postdoctoral researcher studying the systems biology of alcohol addiction (Sybil-AA). Thereafter, he joined AstraZeneca as part the Molecular AI group, developing approaches toward drug design.